Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell LymphomaElise A. Olsen, Jean Nichols, Madeleine Duvic et al.|Journal of Clinical Oncology|2001Cited by 610
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Judith Trotman et al.|The Lancet|2017Cited by 580
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic ModelJulia Scarisbrick, Henry K. Wong, H. Miles Prince et al.|Journal of Clinical Oncology|2015Cited by 419
Sebaceous carcinoma: evidence-based clinical practice guidelinesJoshua L. Owen, Michael K. Wong, Nour Kibbi et al.|The Lancet Oncology|2019Cited by 204
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607)Kevin Kalinsky, John M. Kirkwood, Krista M. Rubin et al.|Cancer|2017Cited by 125